

Yingye Zheng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3869626/publications.pdf>

Version: 2024-02-01

52
papers

1,708
citations

331670

21
h-index

289244

40
g-index

53
all docs

53
docs citations

53
times ranked

2997
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 430-439.	5.4	8
2	Re-calibrating pure risk integrating individual data from two-phase studies with external summary statistics. <i>Biometrics</i> , 2022, 78, 1515-1529.	1.4	2
3	Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. <i>Cancer</i> , 2022, 128, 269-274.	4.1	3
4	Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. <i>Journal of Urology</i> , 2022, 207, 805-813.	0.4	3
5	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 113-119.	0.4	10
6	Associations between Genetic Variants and Blood Biomarkers of One-Carbon Metabolism in Postmenopausal Women from the Women's Health Initiative Observational Study. <i>Journal of Nutrition</i> , 2022, 152, 1099-1106.	2.9	2
7	Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. <i>Cancer Medicine</i> , 2022, , .	2.8	3
8	Developing and evaluating risk prediction models with panel current status data. <i>Biometrics</i> , 2021, 77, 599-609.	1.4	1
9	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. <i>Journal of Urology</i> , 2021, 205, 732-739.	0.4	21
10	Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients. <i>British Journal of Cancer</i> , 2021, 125, 806-815.	6.4	12
11	Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond. <i>Preventive Medicine</i> , 2021, 151, 106595.	3.4	23
12	OUP accepted manuscript. <i>Biostatistics</i> , 2021, , .	1.5	0
13	Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. <i>Journal of the National Cancer Institute</i> , 2020, 112, 238-246.	6.3	35
14	Learning-based biomarker-assisted rules for optimized clinical benefit under a risk constraint. <i>Biometrics</i> , 2020, 76, 853-862.	1.4	2
15	Associations between Plasma Choline Metabolites and Genetic Polymorphisms in One-Carbon Metabolism in Postmenopausal Women: The Women's Health Initiative Observational Study. <i>Journal of Nutrition</i> , 2020, 150, 2874-2881.	2.9	7
16	Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. <i>JAMA Oncology</i> , 2020, 6, e203187.	7.1	30
17	17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 1549-1557.	1.6	48
18	A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 549-557.	2.5	25

#	ARTICLE	IF	CITATIONS
19	Constructing dynamic treatment regimes with shared parameters for censored data. <i>Statistics in Medicine</i> , 2020, 39, 1250-1263.	1.6	7
20	Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 438-445.	3.9	22
21	Receipt of Colonoscopy Following Diagnosis of Advanced Adenomas: An Analysis within Integrated Healthcare Delivery Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 91-98.	2.5	16
22	Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. <i>Gastroenterology</i> , 2018, 154, 2152-2164.e19.	1.3	226
23	Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. <i>European Urology</i> , 2018, 74, 211-217.	1.9	30
24	Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. <i>Journal of the American Statistical Association</i> , 2018, 113, 882-892.	3.1	3
25	Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. <i>European Urology</i> , 2017, 72, 448-454.	1.9	61
26	Improving efficiency in biomarker incremental value evaluation under two-phase designs. <i>Annals of Applied Statistics</i> , 2017, 11, 638-654.	1.1	6
27	Follow-Up of Abnormal Breast and Colorectal Cancer Screening by Race/Ethnicity. <i>American Journal of Preventive Medicine</i> , 2016, 51, 507-512.	3.0	46
28	PD08-02 EVALUATING THE FOUR KALLIKREIN PANEL OF THE 4KSCORE FOR PREDICTION OF HIGH-GRADE PROSTATE CANCER IN MEN IN THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS). <i>Journal of Urology</i> , 2016, 195, .	0.4	2
29	Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. <i>American Journal of Preventive Medicine</i> , 2016, 51, e107-e115.	3.0	67
30	Influence of Age and Comorbidity on Colorectal Cancer Screening in the Elderly. <i>American Journal of Preventive Medicine</i> , 2016, 51, e67-e75.	3.0	24
31	Time to Colonoscopy after Positive Fecal Blood Test in Four U.S. Health Care Systems. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 344-350.	2.5	106
32	Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. <i>Genomics Data</i> , 2015, 6, 154-158.	1.3	7
33	Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study. <i>Cancer</i> , 2015, 121, 3684-3691.	4.1	38
34	Red blood cell folate and plasma folate are not associated with risk of incident colorectal cancer in the Women's Health Initiative observational study. <i>International Journal of Cancer</i> , 2015, 137, 930-939.	5.1	20
35	Assessing Incremental Value of Biomarkers with Multi-phase Nested Case-control Studies. <i>Biometrics</i> , 2015, 71, 1139-1149.	1.4	4
36	A Model to Determine Colorectal Cancer Risk Using Common Genetic Susceptibility Loci. <i>Gastroenterology</i> , 2015, 148, 1330-1339.e14.	1.3	129

#	ARTICLE	IF	CITATIONS
37	Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial. <i>BMC Medical Genetics</i> , 2015, 16, 18.	2.1	17
38	Two-stage biomarker panel study and estimation allowing early termination for futility. <i>Biostatistics</i> , 2015, 16, 799-812.	1.5	2
39	Impact of folic acid fortification on global DNA methylation and one-carbon biomarkers in the Women's Health Initiative Observational Study cohort. <i>Epigenetics</i> , 2014, 9, 396-403.	2.7	37
40	The Colorectal Cancer Screening Process in Community Settings: A Conceptual Model for the Population-Based Research Optimizing Screening through Personalized Regimens Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1147-1158.	2.5	64
41	Estimating Risk With Time-to-Event Data: An Application to the Women's Health Initiative. <i>Journal of the American Statistical Association</i> , 2014, 109, 514-524.	3.1	15
42	Resampling Procedures for Making Inference Under Nested Case-Control Studies. <i>Journal of the American Statistical Association</i> , 2013, 108, 1532-1544.	3.1	18
43	B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 332-343.	4.7	64
44	Homocysteine, cysteine, and risk of incident colorectal cancer in the Women's Health Initiative observational cohort. <i>American Journal of Clinical Nutrition</i> , 2013, 97, 827-834.	4.7	70
45	Evaluating prognostic accuracy of biomarkers in nested case-control studies. <i>Biostatistics</i> , 2012, 13, 89-100.	1.5	45
46	Evaluating the Predictive Value of Biomarkers with Stratified Case-Cohort Design. <i>Biometrics</i> , 2012, 68, 1219-1227.	1.4	20
47	Determinants of Aspirin Metabolism in Healthy Men and Women: Effects of Dietary Inducers of UDP-Glucuronosyltransferases. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 110-118.	1.3	31
48	Assessing Accuracy of Mammography in the Presence of Verification Bias and Intrareader Correlation. <i>Biometrics</i> , 2005, 61, 259-268.	1.4	14
49	Semiparametric estimation of time-dependent ROC curves for longitudinal marker data. <i>Biostatistics</i> , 2004, 5, 615-632.	1.5	58
50	Risk Projection for Time-to-Event Outcome Leveraging Summary Statistics With Source Individual-Level Data. <i>Journal of the American Statistical Association</i> , 0, , 1-13.	3.1	4
51	Targeted Search for Individualized Clinical Decision Rules to Optimize Clinical Outcomes. <i>Statistics in Biosciences</i> , 0, , .	1.2	0
52	Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. <i>Journal of Urology</i> , 0, , .	0.4	1